Explore the potential of gene therapy as a groundbreaking approach to curing diseases, beyond traditional pharmacological ...

A key step to deliver RNAi therapeutics to diverse cell types and tissues beyond the liver from the collaboration of ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

Rona Therapeutics, a global leader in next-generation RNAi medicines, today announced the submission of RN5681 to the ...

Rona Therapeutics, a clinical-stage RNAi company, today announced the recent completion of Cohort 1 dosing in its Phase 1 ...

Ministeerri Fayyaa Itoophiyaa damee fayyaa biyyattii jabeessuuf mootummaa Ameerika waliin waliigaltee deeggarsaa doolaara ...

With six drugs approved for commercial development, Cambridge-based drugmaker Alnylam Pharmaceuticals Inc. is investing $250 ...

PeptiDream (TSE:4587) just logged two meaningful scientific wins, advancing an oral dual IL 17 program into its clinical portfolio and hitting a preclinical siRNA delivery milestone with Alnylam, ...

Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) ...

Chaayinaan naannoo Taayiwaanitti shaakala waraanaa naannoolee ijoo odola kanaa to'achuu fakkaatu gaggeessaa jirti. Kunis ...

VESALIUS-CV was big in 2025, but studies looking at triglycerides, CRISPR, and oral GLP-1s also made the highlight reel.

Leading RNA drug developer Suzhou Ribo Life Science Co. Ltd. passed its hearing for a listing on the Hong Kong Stock Exchange, marking the official launch of its IPO, according to its post-hearing ...